Medtronic, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Danielle Antalffy from UBS maintained a Hold rating on the stock and has a $95.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Danielle Antalffy has given her Hold rating due to a combination of factors affecting Medtronic’s performance. The company reported strong quarterly results with significant growth in the Cardiovascular and Neuroscience segments, driven by the impressive performance of PFA. However, this was offset by weaker results in the Medical Surgical and Diabetes segments. While there is optimism for growth acceleration in these underperforming areas in the latter half of FY26, there remains uncertainty, particularly in the Medical Surgical segment due to competitive pressures.
Despite the solid execution against previous expectations, Antalffy maintains a Neutral stance, reflecting limited confidence in Medtronic’s ability to achieve consistent and sustainable organic sales growth of 6%. The anticipated growth in the Diabetes segment, supported by new product launches, provides some optimism, but the unclear outlook for Medical Surgical, which constitutes a significant portion of total sales, tempers the overall growth expectations. Therefore, the Hold rating reflects a cautious approach given the mixed performance across the company’s business segments.
In another report released today, Goldman Sachs also upgraded the stock to a Hold with a $111.00 price target.
Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is neutral on the stock.